ASTH Stock Forecast & Price Target

Astrana Health is viewed favorably because its value-based care model is proving resilient, with 3Q26 revenue of $1,023.6mm up 7.1% year over year, adjusted EBITDA of $77.2mm above expectations, and gross margin expanding 190bps to 12.1%. Its largest Care Partners segment grew 7.9% to $968.8mm, while FY26 guidance was narrowed but midpoints were left unchanged, reflecting confidence in continued execution despite ongoing reinvestment. The bullish case is also supported by sub-5.2% year-to-date medical cost trend, ~82% full-risk capitation by year-end, and $120.4M of gross shared savings across all 8 ACOs in PY 2024, underscoring operating leverage and durable upside potential.

Astrana Health is viewed cautiously because the comparable CVS ACO REACH data suggest weak economics in value-based care, with only about $3.2B in PY 2024 spending and an overall savings rate of just 3% despite an 83% quality score. The fact that Oak Street delivered a 21% savings rate but only a 56% quality score underscores the tradeoff between cost reduction and care quality, which is concerning for a patient-centered, outcomes-based platform. For a company that relies heavily on its Care Partners segment and senior/chronic-care populations, low systemwide savings and uneven quality execution raise questions about scalability, margin durability, and clinical performance.